Search
×
FR

Placeholder headline

This is just a placeholder headline

API TR 5C3: Calculating Performance Properties of Pipe Used as Casing or Tubing

$

422

BUY NOW

Placeholder headline

This is just a placeholder headline

API STD 671: Special Purpose Couplings for Petroleum, Chemical and Gas Industry Services

$

502

BUY NOW

Placeholder headline

This is just a placeholder headline

Technical Report API TBD-10: Chapter 10 Surface and Interfacial Tension

$

176

BUY NOW

Placeholder headline

This is just a placeholder headline

API STD 671: Special Purpose Couplings for Petroleum, Chemical and Gas Industry Services: Errata 2

$

0

BUY NOW

Placeholder headline

This is just a placeholder headline

MSS SP-44-2026: Steel Pipeline Flanges

$

450

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 576: Inspection of Pressure-relieving Devices

$

460

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 591: Process Valve Qualification Procedure

$

226

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 576: Inspection of Pressure-relieving Devices: Addendum 1

$

0

BUY NOW

ISO 22442:2010

ISO 22442:2010 Medical devices utilizing animal tissues and their derivatives – Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes

CDN $173.00

SKU: f5875f42acc2 Category:

Description

ISO/TR 22442-4:2010 offers suggestions for designing and conducting validation assays to help determine if processes used in the manufacture of medical devices derived from non-viable animal tissues might serve to reduce the risk of iatrogenic transmission of transmissible spongiform encephalopathies (TSEs).

The TSE-removal methods used to process animal tissues should also reduce the risk of transmitting TSE infections via non-viable tissues of human origin; this Technical Report does not address this issue. Some current information on human tissues and TSEs is presented which may be applied by analogy to other animal tissues.

ISO/TR 22442-4:2010 does not intend to imply a need for validation of methods involving specific materials identified as having a “negligible risk” of contamination with TSE agents as listed in Annex C of ISO 22442-1:2007.

It is intended to clarify final draft international standards included in the ISO 22442 series, as well as in ISO 14160.

ISO/TR 22442-4:2010 builds upon the specific discussion in ISO 22442-3 relative to TSE agents and attempts to summarize the current state of the art in the arena of TSE agent elimination. As the understanding of inactivation and elimination of TSE agents evolves, this document will be revised when possible.

Edition

1

Published Date

2010-11-16

Status

PUBLISHED

Pages

14

Language Detail Icon

English

Format Secure Icon

Secure PDF

Abstract

ISO/TR 22442-4:2010 offers suggestions for designing and conducting validation assays to help determine if processes used in the manufacture of medical devices derived from non-viable animal tissues might serve to reduce the risk of iatrogenic transmission of transmissible spongiform encephalopathies (TSEs).

The TSE-removal methods used to process animal tissues should also reduce the risk of transmitting TSE infections via non-viable tissues of human origin; this Technical Report does not address this issue. Some current information on human tissues and TSEs is presented which may be applied by analogy to other animal tissues.

ISO/TR 22442-4:2010 does not intend to imply a need for validation of methods involving specific materials identified as having a "negligible risk" of contamination with TSE agents as listed in Annex C of ISO 22442-1:2007.

It is intended to clarify final draft international standards included in the ISO 22442 series, as well as in ISO 14160.

ISO/TR 22442-4:2010 builds upon the specific discussion in ISO 22442-3 relative to TSE agents and attempts to summarize the current state of the art in the arena of TSE agent elimination. As the understanding of inactivation and elimination of TSE agents evolves, this document will be revised when possible.

Previous Editions

Can’t find what you are looking for?

Please contact us at: